ELISA/assay

Chicken Acid Phosphatase 5 TartRate Resistant ELISA Kit

MBS738064

48-Strip-Wells

470 USD

ELISA Kit

Chicken Acid Phosphatase 5 TartRate Resistant ELISA Kit

Acid Phosphatase 5 TartRate Resistant

ACP5; Tartrate-resistant acid phosphatase type 5; tartrate-resistant acid phosphatase type 5; TrATPase; tartrate-resistant acid ATPase; acid phosphatase 5, tartrate resistant; Tartrate-resistant acid ATPase; TrATPase; Type 5 acid phosphatase

ACP5

ACP5; ACP5; TRAP; SPENCDI; TR-AP; TrATPase

PPA5_HUMAN

Chicken

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

Cardiovascular

For samples: Serum, plasma, cell culture supernatants, body fluid and tissue homogenate . INTENDED USE This TRACP5 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Chicken TRACP5. This ELISA kit for research use only, not for therapeutic or diagnostic applications! br>. PRINCIPLE OF THE ASSAY TRACP5 ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-TRACP5 antibody and an TRACP5-HRP conjugate. The assay sample and buffer are incubated together with TRACP5-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the TRACP5 concentration since TRACP5 from samples and TRACP5-HRP conjugate compete for the anti-TRACP5 antibody binding site. Since the number of sites is limited, as more sites are occupied by TRACP5 from the sample, fewer sites are left to bind TRACP5-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The TRACP5 concentration in each sample is interpolated from this standard curve.

48146273

CAG33359.1

P13686

36,599 Da

Defective AMN Causes Hereditary Megaloblastic Anemia 1 Pathway (906000); Defective BTD Causes Biotidinase Deficiency Pathway (906015); Defective CD320 Causes Methylmalonic Aciduria Pathway (906012); Defective CUBN Causes Hereditary Megaloblastic Anemia 1 Pathway (906001); Defective GIF Causes Intrinsic Factor Deficiency Pathway (906004); Defective HLCS Causes Multiple Carboxylase Deficiency Pathway (906014); Defective LMBRD1 Causes Methylmalonic Aciduria And Homocystinuria Type CblF Pathway (906003); Defective MMAA Causes Methylmalonic Aciduria Type CblA Pathway (906010); Defective MMAB Causes Methylmalonic Aciduria Type CblB Pathway (906009); Defective MMACHC Causes Methylmalonic Aciduria And Homocystinuria Type CblC Pathway (906005)

This gene encodes an iron containing glycoprotein which catalyzes the conversion of orthophosphoric monoester to alcohol and orthophosphate. It is the most basic of the acid phosphatases and is the only form not inhibited by L(+)-tartrate. [provided by RefSeq, Aug 2008]

ACP5: Involved in osteopontin/bone sialoprotein dephosphorylation. Its expression seems to increase in certain pathological states such as Gaucher and Hodgkin diseases, the hairy cell, the B-cell, and the T-cell leukemias. Defects in ACP5 are the cause of spondyloenchondrodysplasia with immune dysregulation (SPENCDI). A disease characterized by vertebral and metaphyseal dysplasia, spasticity with cerebral calcifications, and strong predisposition to autoimmune diseases. The skeletal dysplasia is characterized by radiolucent and irregular spondylar and metaphyseal lesions that represent islands of chondroid tissue within bone. ACP5 inactivating mutations result in a functional excess of phosphorylated osteopontin causing deregulation of osteopontin signaling and consequential autoimmune disease. Belongs to the metallophosphoesterase superfamily. Purple acid phosphatase family. Protein type: Cofactor and Vitamin Metabolism - riboflavin; Phosphatase; EC 3.1.3.2; Motility/polarity/chemotaxis. Chromosomal Location of Human Ortholog: 19p13.2. Cellular Component: lysosome; integral to membrane; cytosol. Molecular Function: acid phosphatase activity; ferric iron binding; ferrous iron binding. Biological Process: negative regulation of interleukin-12 production; vitamin metabolic process; negative regulation of nitric oxide biosynthetic process; response to lipopolysaccharide; negative regulation of tumor necrosis factor production; negative regulation of interleukin-1 beta production; negative regulation of superoxide release; riboflavin metabolic process; defense response to Gram-positive bacterium; dephosphorylation; response to cytokine stimulus; negative regulation of inflammatory response; water-soluble vitamin metabolic process; bone resorption. Disease: Spondyloenchondrodysplasia With Immune Dysregulation

48-Strip-Wells

470 USD

96-Strip-Wells

675